Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH
07 oct. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology to Participate in Two Upcoming Investor Conferences
08 sept. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Appoints Dr. Stephen Dale as Chief Medical Officer
25 août 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Reports Second Quarter 2020 Financial Results
06 août 2020 16h05 HE
|
Kura Oncology, Inc.
– Anticipate preliminary data presentation of menin inhibitor program, KO-539, at ASH – – Continued progress in registration-directed trial of tipifarnib in HRAS mutant HNSCC – – Opportunity to...
Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference
04 août 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Second Quarter 2020 Financial Results
30 juil. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology to Participate in JMP Securities Hematology & Oncology Forum
11 juin 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program
13 mai 2020 17h00 HE
|
Kura Oncology, Inc.
SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020
07 mai 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock
06 mai 2020 09h00 HE
|
Kura Oncology, Inc.
SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...